Boston Scientific

Health Care Health Care Equipment Marlborough, Massachusetts Last filing Feb 17, 2026 · FY2025

                    Revenue
                    FY2025
                
$20.1B
                    3y CAGR +16.5%
                    
                    P93
                    
                    n/a
                    
                    Net income
                    FY2025
                
$2.9B
                    Net margin +14.4%
                    
                    P62
                    
                    n/a
                    
                    Total assets
                    FY2025
                
$43.7B
                    ROA +6.6%
                    
                    P58
                    
                    n/a
                    
                    Operating cash flow
                    FY2025
                
$4.5B
                    FCF margin +18.2%
                    
                    P65
                    
                    n/a

19 yrs · FY2007–FY2025 9 filed · 0 derived · 0 blank

1Y 3Y 5Y 10Y

Dollars % of revenue % of assets YoY % CAGR

Each cell as a share of that year’s revenue.

Balance Sheet

Assets, liabilities, and equity

31 accounts · 1 year

Total assets $43.7B

Total liabilities $5.4B

Shareholders equity $24.2B

Account	2025	Trend
Assets
Cash and Cash Equivalents	9.8%
Short Term Investments	0.0%
Accounts Receivable	15.2%
Inventory	14.7%
Prepaid Expenses	3.3%
Total Current Assets	43.8%
Property,Plant and Equipment	20.1%
Operating Lease Assets	2.3%
Goodwill	91.1%
Intangible Assets	35.0%
Long Term Investments	2.0%
Deferred Tax Assets	18.3%
Other Noncurrent Assets	9.3%
Total Assets	217.6%
Liabilities
Accounts Payable	5.7%
Accrued Liabilities	15.9%
Current Portion of Long Term Debt	1.5%
Other Current Liabilities	4.0%
Total Current Liabilities	27.1%
Deferred Tax Liabilities	1.1%
Other Noncurrent Liabilities	12.0%
Total Liabilities	27.1%
Equity
Preferred Stock	0.0%
Common Stock	0.1%
Additional Paid In Capital	107.1%
Retained Earnings	27.8%
Treasury Stock	11.2%
Accumulated Other Comprehensive Income	-3.0%
Noncontrolling Interest	1.2%
Total Stockholders Equity	120.7%
Total Liabilitiesand Equity	217.6%

Income Statement

Revenue, expense, and profitability

20 accounts · 1 year

Revenue $20.1B

Operating income $3.6B

Net income $2.9B

Account	2025	Trend
IncomeStatement
Revenues Total Revenue	100.0%
Expenses Cost of Revenue	31.0%
Expenses Research and Development	10.2%
Expenses Selling,General and Administrative	34.3%
Expenses Depreciation and Amortization	6.8%
Expenses Share Based Compensation	1.5%
Expenses Restructuring and Asset Impairment	0.5%
Expenses Operating Expenses	51.0%
Other Income Expense Gross Profit	69.0%
Other Income Expense Operating Income	18.0%
Other Income Expense Interest Expense	1.7%
Other Income Expense Other Income/expense	-1.1%
Other Income Expense Income Before Tax	16.9%
Income Tax Income Tax Expense	2.5%
net Income net Income	14.4%
net Income Comprehensive Income	10.0%
Earnings Per Share Basic Eps	0.0%
Earnings Per Share Diluted Eps	0.0%
Earnings Per Share Weighted Average Shares Basic	7.4%
Earnings Per Share Weighted Average Shares Diluted	7.4%

Cash Flow Statement

Operating, investing, and financing flows

19 accounts · 1 year

Operating cash flow $4.5B

Investing cash flow $-2.6B

Financing cash flow $-395.0M

Account	2025	Trend
CashFlow
Operating Activities net Income	14.4%
Operating Activities Depreciation and Amortization	2.3%
Operating Activities Stock Based Compensation	1.5%
Operating Activities Deferred Income Taxes	-0.1%
Operating Activities Changes In Operating Assets and Liabilities	2.3%
Operating Activities Other Non Cash Items	0.2%
Operating Activities net Cash From Operating Activities	22.6%
Investing Activities Capital Expenditures	4.4%
Investing Activities Business Acquisitions	7.9%
Investing Activities Other Investing Activities	-0.4%
Investing Activities net Cash From Investing Activities	-13.2%
Financing Activities Proceeds From Debt	7.8%
Financing Activities Proceeds From Stock Issuance	1.4%
Financing Activities Other Financing Activities	0.0%
Financing Activities net Cash From Financing Activities	-2.0%
Cash Reconciliation Effect of Exchange Rate On Cash	0.2%
Cash Reconciliation net Change In Cash	7.7%
Cash Reconciliation Cash At Beginning of Period	10.7%
Cash Reconciliation Cash At End of Period	10.7%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 1 year

Ratio	2025
Profitability
Gross margin	+69.0%
Operating margin	+18.0%
Net margin	+14.4%
FCF margin	+18.2%
Growth
Revenue CAGR (3y)	+16.5%
Returns
ROE	+11.9%
ROA	+6.6%
ROIC	+13.7%
Liquidity
Current ratio	1.62x
Quick ratio	0.92x
Leverage
D/E	0.22x
Interest coverage	10.35x
Efficiency
Asset turnover	0.46x
Cash conversion cycle	+161d

Valuation

Price against fundamentals

FY2025 fundamentals · no price

No price data cached, so there is nothing to multiply. Load prices from the Stock Data tab and this panel reprices itself.

Notes

Your annotations

Not watched

Boston Scientific

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Assets, liabilities, and equity

Revenue, expense, and profitability

Operating, investing, and financing flows

Margins, returns, liquidity, leverage, efficiency

Price against fundamentals

Your annotations

One-year price and volume history

Price data unavailable

Recent price history